v3.26.1
Consolidated cash flow statements - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Statement [line items]        
Net income $ 3,257 $ 4,024 $ 6,413 $ 7,633
Reversal of non-cash items and other adjustments 3,377 2,954 5,868 5,666
Dividends received from associated companies and others 1 1 1 1
Interest received 44 39 127 161
Interest paid (339) (248) (540) (480)
Other financial receipts   398   398
Other financial payments (41) 8 (53) (13)
Income taxes paid (398) (675) (1,185) (1,215)
Net cash flows from operating activities before working capital and provision changes 5,901 6,501 10,631 12,151
Payments out of provisions and other net cash movements in non-current liabilities (251) (279) (518) (516)
Changes in working capital and other operating cash flow items 232 442 (555) (1,326)
Net cash flows from operating activities 5,882 6,664 9,558 10,309
Purchases of property, plant and equipment (321) (331) (667) (585)
Proceeds from sale of property, plant and equipment 26 1 31 11
Purchases of intangible assets (437) (227) (898) (1,467)
Purchases of financial assets (16) (22) (40) (40)
Proceeds from sale of financial assets 49 20 86 45
Acquisitions of businesses (23) (127) (11,704) (127)
Acquisitions applying the optional concentration test (2,720) (1,537) (2,720) (1,537)
Divestments of businesses, net 62 (11) 60 (15)
Investments in time deposits and marketable securities (30) (36) (60) (73)
Proceeds from time deposits and from sale of marketable securities 87 30 856 1,881
Other investing cash flows, net 218 (3) 215 (6)
Net cash flows (used in)/from investing activities (3,105) (2,243) (14,841) (1,913)
Dividends paid to shareholders of Novartis AG (2,871) (2,485) (9,068) (7,818)
Purchases of treasury shares (1,199) (2,714) (3,074) (5,430)
Proceeds from exercised options and other treasury share transactions, net 14 20 14 21
Proceeds from non-current financial debts 1,982   12,900  
Repayments of the current portion of non-current financial debts (20) (603) (39) (1,613)
Change in current financial debts 208 850 955 1,406
Payments of lease liabilities (67) (66) (140) (135)
Other financing cash flows, net (67) (215) 11 (192)
Net cash flows from/(used in) financing activities (2,020) (5,213) 1,559 (13,761)
Net change in cash and cash equivalents before effect of exchange rate changes 757 (792) (3,724) (5,365)
Effect of exchange rate changes on cash and cash equivalents (18) 382 (95) 562
Net change in cash and cash equivalents 739 (410) (3,819) (4,803)
Cash and cash equivalents at beginning of period 6,877 7,066 11,435 11,459
Cash and cash equivalents at end of period $ 7,616 $ 6,656 $ 7,616 $ 6,656